A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Beyond Spring Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 11,700 shares of BYSI stock, worth $20,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,700
Previous 12,500 6.4%
Holding current value
$20,124
Previous $30,000 13.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.74 - $2.47 $1,392 - $1,976
-800 Reduced 6.4%
11,700 $26,000
Q2 2024

Aug 09, 2024

BUY
$1.76 - $3.6 $22,000 - $45,000
12,500 New
12,500 $30,000
Q2 2023

Aug 11, 2023

SELL
$0.89 - $1.39 $99,319 - $155,117
-111,595 Reduced 91.19%
10,776 $13,000
Q1 2023

May 12, 2023

BUY
$1.06 - $3.05 $129,713 - $373,231
122,371 New
122,371 $137,000
Q3 2022

Nov 14, 2022

SELL
$0.97 - $1.81 $190,084 - $354,693
-195,963 Reduced 53.4%
170,996 $169,000
Q2 2022

Aug 12, 2022

BUY
$1.13 - $2.66 $95,582 - $224,998
84,586 Added 29.96%
366,959 $528,000
Q1 2022

May 13, 2022

BUY
$1.68 - $5.01 $423,482 - $1.26 Million
252,073 Added 831.92%
282,373 $621,000
Q4 2021

Feb 11, 2022

BUY
$4.02 - $16.84 $121,805 - $510,252
30,300 New
30,300 $137,000
Q2 2021

Aug 13, 2021

SELL
$9.37 - $12.12 $1.16 Million - $1.5 Million
-123,800 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$10.61 - $15.77 $264,846 - $393,650
24,962 Added 25.26%
123,800 $1.37 Million
Q4 2020

Feb 10, 2021

BUY
$10.21 - $17.31 $567,063 - $961,397
55,540 Added 128.27%
98,838 $1.21 Million
Q3 2020

Nov 13, 2020

SELL
$9.99 - $16.13 $316,702 - $511,353
-31,702 Reduced 42.27%
43,298 $576,000
Q2 2020

Aug 13, 2020

BUY
$11.21 - $18.15 $840,750 - $1.36 Million
75,000 New
75,000 $1.13 Million

Others Institutions Holding BYSI

About BeyondSpring Inc.


  • Ticker BYSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,928,900
  • Market Cap $67M
  • Description
  • BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...
More about BYSI
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.